Partners


Freenome is working with top pharmaceutical companies, integrated health systems, 
and academic institutions to use its AI genomics platform to address cancer’s most
pressing challenges. 
Together, we're proud to be at the forefront in developing the next generation of
genomic screening tools and precision oncology therapies. 

 

  • Novel biomarker discovery

  • New target discovery

  • Resistance pathway analysis

  • Response prediction for immuno-oncology and epigenetic modifiers

 

Investors


Since its founding in 2014, the promise of Freenome’s AI genomics platform has
attracted over $78 million in support from more than a dozen leading healthcare and technology
investors.

 
fnm_website@2x_logo1.jpg
fnm_website@2x_logo2.jpg
fnm_website@2x_logo3.jpg
fnm_website@2x_logo4.jpg